Iron Overload Clinical Trial
Official title:
"Iron Overload and Endocrinological Diseases"
Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage to these organs, with variable degrees of endocrine and organ failure. Although patients with iron overload often present endocrine disorders, the pathogenetic mechanisms underlying endocrinopathies are not completely clear. In particular it is not elucidated if the spectrum of endocrinopathies could change with advancing age. All endocrinological comorbidities can develop from a primary damage of the target gland, from pituitary secondary failure or from both. The aim of this study is to investigate the prevalence of endocrinological diseases in adult patients with iron overload due to β-thalassemia or hemochromatosis and their impact on well-being and quality of life. The study design is a prospective cross-sectional clinical study. All subjects enrolled will be evaluated for the endocrine diseases. The study protocol will include data collection from family and patients' history of diseases, physical examination, hormonal assessment for all endocrine axes and instrumental examinations. The results will provide evidence on the prevalence of endocrine diseases in patients with iron overload and will add information to characterize the type and the degree of endocrine deficiencies, and on the pathogenic mechanisms involved, in order to individualize diagnostic and therapeutic approaches.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04423237 -
Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT02833493 -
Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Recruiting |
NCT00378469 -
Study of the Effects of Muscular Activity on Iron Metabolism
|
N/A | |
Completed |
NCT00117507 -
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|
Phase 4 | |
Completed |
NCT00138684 -
Cytochrome P450 2E1 and Iron Overload
|
Phase 2 | |
Completed |
NCT03990181 -
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
|
N/A | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Active, not recruiting |
NCT01443195 -
Iron Metabolism in Small Pre Term Newborns
|
N/A | |
Completed |
NCT01546415 -
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
|
Phase 4 | |
Completed |
NCT01572818 -
Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
|
N/A | |
Not yet recruiting |
NCT00980421 -
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Recruiting |
NCT05294471 -
Fully Automated High-Throughput Quantitative MRI of the Liver
|
||
Completed |
NCT03591575 -
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
|
Phase 4 | |
Active, not recruiting |
NCT00907283 -
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
|
Phase 2 |